HMBG-1: A Biomarker in the Management of Diabetic Retinopathy
HMGB-1: un biomarcador en el manejo de la retinopatía diabética
Burak Bilgin, Necla Benlier, Ömer Aydın Yıldırım, Fatih Özbakış, Nuri Orhan, Nihal Cesur Özbakış, Hüseyin Gürbüz
Abstract
Introduction: High mobility group box (HMGB)-1 protein is a promising prognostic marker for predicting the course of retinopathy and the prognosis in patients with diabetic retinopathy (DR). The aim of this study is to investigate whether serum HMGB-1 protein levels can be used as a biomarker about the severity of the disease in patients with diabetic retinopathy.
Material and methods: This study was carried out in the internal medicine and ophthalmology departments of the Gaziantep Medicalpark Hospital. The records of 50 patients diagnosed with type 2 diabetes mellitus with diabetic retinopathy and 47 healthy subjects who applied to our clinic between January 2016 and December 2018 were retrospectively scanned. Five cc of venous blood was taken from the patients, and control groups were included in the study for routine laboratory tests and serum HMGB-1 levels to be studied under appropriate conditions. Human HMGB-1 levels were measured using the ELISA method.
Results: There was a significant difference among the groups in terms of HMGB-1 levels (p<0.001) (Table-1). There was a positive correlation between blood glucose and HMGB-1 in the diabetic retinopathy group (Spearman's rho (ρ)=0.07). Similarly, there was a positive correlation between HbA1c and HMGB-1 levels in the diabetic retinopathy group. (Spearman's rho (ρ)=0.06).
Conclusions: Our study suggests that HMGB-1 may be a useful biomarker in managing DR, aiding in the prediction and treatment of microvascular complications.
Keywords
Resumen
Introducción: La proteína del grupo de alta movilidad (HMGB) -1 es un marcador pronóstico prometedor para predecir el curso de la retinopatía y el pronóstico en pacientes con retinopatía diabética (RD). El objetivo de este estudio es investigar si los niveles séricos de proteína HMGB-1 pueden utilizarse como biomarcador sobre la gravedad de la enfermedad en pacientes con retinopatía diabética.
Material y métodos: Este estudio se llevó a cabo en los departamentos de medicina interna y oftalmología del Hospital Gaziantep Medicalpark. Se escanearon retrospectivamente los registros de 50 pacientes diagnosticados con diabetes mellitus tipo 2 con retinopatía diabética y 47 sujetos sanos que solicitaron atención a nuestra clínica entre enero de 2016 y diciembre de 2018. Se tomaron cinco cc de sangre venosa de los pacientes y se incluyeron grupos de control en el estudio para realizar pruebas de laboratorio de rutina y estudiar los niveles séricos de HMGB-1 en condiciones apropiadas. Los niveles de HMGB-1 humana se midieron mediante el método ELISA.
Resultados: Hubo una diferencia significativa entre los grupos en términos de niveles de HMGB-1 (p<0,001) (Tabla 1). Hubo una correlación positiva entre la glucosa en sangre y la HMGB-1 en el grupo de retinopatía diabética (rho de Spearman (ρ) = 0,07). De manera similar, hubo una correlación positiva entre los niveles de HbA1c y HMGB-1 en el grupo de retinopatía diabética. (Rho de Spearman (ρ) = 0,06).
Conclusiones: Nuestro estudio sugiere que HMGB-1 puede ser un biomarcador útil en el manejo de la RD, ayudando en la predicción y el tratamiento de complicaciones microvasculares.
Palabras clave
References
1.Zhao H, Zhang J, Yu J. HMGB-1 as a Potential Target for the Treatment of Diabetic Retinopathy. Med Sci Monit. 2015;21:3062-7. doi: 10.12659/MSM.894453.
2.Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273. doi: 10.1155/2016/2156273.
3.Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem. 1973;38(1):14-9. doi: 10.1111/j.1432-1033.1973.tb03026.x.
4.Müller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med. 2004;255(3):332-43. doi: 10.1111/j.1365-2796.2003.01296.x.
5.Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest. 2009;89(8):948-59. doi: 10.1038/labinvest.2009.47.
6.Thomas JO, Travers AA. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Sci. 2001;26(3):167-74. doi: 10.1016/s0968-0004(01)01801-1.
7.Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331-42. doi: 10.1038/nri1594.
8.Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S5-20. doi: 10.2337/diacare.26.2007.s5.
9.Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343-58. doi: 10.1016/j.preteyeres.2011.05.002.
10.Cox SS, Speaker KJ, Beninson LA, Craig WC, Paton MM, Fleshner M. Adrenergic and glucocorticoid modulation of the sterile inflammatory response. Brain Behav Immun. 2014;36:183-92. doi: 10.1016/j.bbi.2013.11.018.
11.Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. doi: 10.1038/nri2925.
12.Yang H, Wang H, Andersson U. Targeting Inflammation Driven by HMGB1. Front Immunol. 2020;11:484. doi: 10.3389/fimmu.2020.00484.
13.El-Asrar AM, Nawaz MI, Kangave D, Geboes K, Ola MS, Ahmad S, et al. High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis. 2011;17:1829-38.
14.Kim J, Kim CS, Sohn E, Kim JS. Cytoplasmic translocation of high-mobility group box-1 protein is induced by diabetes and high glucose in retinal pericytes. Mol Med Rep. 2016;14(4):3655-61. doi: 10.3892/mmr.2016.5702.
15.Mohammad G, Jomar D, Siddiquei MM, Alam K, Abu El-Asrar AM. High-Mobility Group Box-1 Protein Mediates the Regulation of Signal Transducer and Activator of Transcription-3 in the Diabetic Retina and in Human Retinal Müller Cells. Ophthalmic Res. 2017;57(3):150-60. doi: 10.1159/000448115.
16.Nogueira-Machado JA, de Oliveira Volpe CM. HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(3):201-9. doi: 10.2174/187221412802481784.
17.Chen XL, Zhang XD, Li YY, Chen XM, Tang DR, Ran RJ. Involvement of HMGB1 mediated signalling pathway in diabetic retinopathy: evidence from type 2 diabetic rats and ARPE-19 cells under diabetic condition. Br J Ophthalmol. 2013;97(12):1598-603. doi: 10.1136/bjophthalmol-2013-303736.
18.Mohammad G, Siddiquei MM, Othman A, Al-Shabrawey M, Abu El-Asrar AM. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res. 2013;107:101-9. doi: 10.1016/j.exer.2012.12.009.
19.Jiang S, Chen X. HMGB1 siRNA can reduce damage to retinal cells induced by high glucose in vitro and in vivo. Drug Des Devel Ther. 2017;11:783-95. doi: 10.2147/DDDT.S129913.
20.Yıldırım OA, Benlier N, Cicek H, Gurbuz H, Orhan N, Sever ON, et al. The role of high mobility group box protein-1 in bacterial sepsis. Acta Med Nicomed. 2022;5(1):27-31.
21.Giurdanella G, Motta C, Muriana S, Arena V, Anfuso CD, Lupo G, et al. Cytosolic and calcium-independent phospholipase A(2) mediate glioma-enhanced proangiogenic activity of brain endothelial cells. Microvasc Res. 2011;81(1):1-17. doi: 10.1016/j.mvr.2010.11.005.
22.Lupo G, Anfuso CD, Ragusa N, Strosznajder RP, Walski M, Alberghina M. t-Butyl hydroperoxide and oxidized low density lipoprotein enhance phospholipid hydrolysis in lipopolysaccharide-stimulated retinal pericytes. Biochim Biophys Acta. 2001;1531(1-2):143-55. doi: 10.1016/s1388-1981(01)00102-0.
23.Dvoriantchikova G, Hernandez E, Grant J, Santos AR, Yang H, Ivanov D. The high-mobility group box-1 nuclear factor mediates retinal injury after ischemia reperfusion. Invest Ophthalmol Vis Sci. 2011;52(10):7187-94. doi: 10.1167/iovs.11-7793.
24.Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010;33(4):861-8. doi: 10.2337/dc09-1799.
25.Li YH, Kuo CH, Shi GY, Wu HL. The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci. 2012;19(1):34. doi: 10.1186/1423-0127-19-34.
26.Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009;52(8):1665-8. doi: 10.1007/s00125-009-1394-8.
27.Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med. 2008;36(8):2407-13. doi: 10.1097/CCM.0b013e318180b3ba.
28.Fu D, Tian X. Effect of high mobility group box 1 on the human retinal pigment epithelial cell in high-glucose condition. Int J Clin Exp Med. 2015;8(10):17796-803.
29.Abu El-Asrar AM, Nawaz MI, Kangave D, Abouammoh M, Mohammad G. High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy. Mediators Inflamm. 2012;2012:697489. doi: 10.1155/2012/697489.
30.Shen Y, Cao H, Chen F, Suo Y, Wang N, Xu X. A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy. Acta Ophthalmol. 2020;98(2):e212-e216. doi: 10.1111/aos.14228.
31.Wang H, Qu H, Deng H. Plasma HMGB-1 Levels in Subjects with Obesity and Type 2 Diabetes: A Cross-Sectional Study in China. PLoS One. 2015;10(8):e0136564. doi: 10.1371/journal.pone.0136564.
32.Wang Y, Zhong J, Zhang X, Liu Z, Yang Y, Gong Q, Ren B. The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes. J Diabetes Res. 2016;2016:2543268. doi: 10.1155/2016/2543268.
33.Jiang S, Chen X. Expression of High-Mobility Group Box 1 Protein (HMGB1) and Toll-Like Receptor 9 (TLR9) in Retinas of Diabetic Rats. Med Sci Monit. 2017;23:3115-22. doi: 10.12659/msm.902193.
34.Yu Y, Yang L, Lv J, Huang X, Yi J, Pei C, et al. The role of high mobility group box 1 (HMGB-1) in the diabetic retinopathy inflammation and apoptosis. Int J Clin Exp Pathol. 2015;8(6):6807-13.
35.Mohammad G, Alam K, Nawaz MI, Siddiquei MM, Mousa A, Abu El-Asrar AM. Mutual enhancement between high-mobility group box-1 and NADPH oxidase-derived reactive oxygen species mediates diabetes-induced upregulation of retinal apoptotic markers. J Physiol Biochem. 2015;71(3):359-72. doi: 10.1007/s13105-015-0416-x.
Submitted date:
02/28/2024
Reviewed date:
05/20/2024
Accepted date:
06/05/2024
Publication date:
06/18/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email